{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:02:12Z","timestamp":1773226932538,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clml.2024.06.008","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T18:20:51Z","timestamp":1719944451000},"page":"789-795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Survival Among Patients With Multiple Myeloma in the United States Military Health System Compared to the Surveillance, Epidemiology, and End Results (SEER) Program"],"prefix":"10.1016","volume":"24","author":[{"given":"Alexander","family":"Dew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7840-2806","authenticated-orcid":false,"given":"Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Darmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Roswarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Shriver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangmin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alden","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.06.008_bib0001","unstructured":"American Cancer Society. Cancer Facts & Figures 2024. Atlanta: American Cancer Society; 2024. https:\/\/www.cancer.org\/cancer\/types\/multiple-myeloma\/about\/key-statistics.html. Accessed on February 22, 2024."},{"issue":"10068","key":"10.1016\/j.clml.2024.06.008_bib0002","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clml.2024.06.008_bib0003","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2024.06.008_bib0004","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1159\/000514671","article-title":"Survival disparities in multiple myeloma by health insurance status among US non-elderly adults: a SEER-based comparative analysis","volume":"144","author":"Huang","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2024.06.008_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106542","article-title":"Association of insurance disparities and survival in adults with multiple myeloma: a non-concurrent cohort study","volume":"104","author":"Makhani","year":"2021","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.clml.2024.06.008_bib0006","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10552-021-01454-w","article-title":"Differences in survival among multiple myeloma patients in the United States SEER population by neighborhood socioeconomic status and race\/ethnicity","volume":"32","author":"Casta\u00f1eda-Avila","year":"2021","journal-title":"Cancer Causes Control"},{"issue":"20","key":"10.1016\/j.clml.2024.06.008_bib0007","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/cncr.30183","article-title":"Impact of marital status, insurance status, income, and race\/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States","volume":"122","author":"Costa","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.06.008_bib0008","article-title":"Racial differences in treatment and survival among older patients with multiple myeloma","author":"Wang","year":"2024","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.clml.2024.06.008_bib0009","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1158\/1055-9965.EPI-17-0822","article-title":"Survival among Lung Cancer Patients in the U.S. Military Health System: A Comparison with the SEER Population","volume":"27","author":"Lin","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"13","key":"10.1016\/j.clml.2024.06.008_bib0010","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1002\/cncr.32884","article-title":"Survival among patients with glioma in the US Military Health System: a comparison with patients in the surveillance, epidemiology, and end results program","volume":"126","author":"Lin","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.clml.2024.06.008_bib0011","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1158\/1055-9965.EPI-20-1267","article-title":"Comparison of survival among colon cancer patients in the U.S. Military Health System and Patients in the Surveillance, Epidemiology, and End Results (SEER) Program","volume":"30","author":"Lin","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"10.1016\/j.clml.2024.06.008_bib0012","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41416-022-02136-3","article-title":"Five-year survival of patients with late-stage prostate cancer: comparison of the Military Health System and the U.S. general population","volume":"128","author":"Lin","year":"2023","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.clml.2024.06.008_bib0013","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/j.clbc.2021.11.010","article-title":"Survival among breast cancer patients: comparison of the U.S. Military Health System with the Surveillance, Epidemiology and End Results Program","volume":"22","author":"Lin","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"10.1016\/j.clml.2024.06.008_bib0014","article-title":"Soft-tissue Sarcoma Survival in the US Military Health System: comparison With the SEER Program","volume":"6","author":"Anderson","year":"2022","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"key":"10.1016\/j.clml.2024.06.008_bib0015","unstructured":"Cancer Program Standards 2016: Ensuraing patient-centered care. https:\/\/www.facs.org\/media\/t5spw4jo\/2016-coc-standards-manual_interactive-pdf.pdf. Accessed February 23, 2024."},{"key":"10.1016\/j.clml.2024.06.008_bib0016","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. https:\/\/seer.cancer.gov\/Accessed Accessed February 23, 2024."},{"key":"10.1016\/j.clml.2024.06.008_bib0017","unstructured":"International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3). World Health Organization. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/96612\/9789241548496_eng.pdf; Accessed on April 13, 2021."},{"issue":"1","key":"10.1016\/j.clml.2024.06.008_bib0018","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.06.008_bib0019","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2024.06.008_bib0020","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2024.06.008_bib0021","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2011.35.6758","article-title":"Survival of older patients with cancer in the Veterans health administration versus fee-for-service Medicare","volume":"30","author":"Landrum","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.06.008_bib0022","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","article-title":"Financial insolvency as a risk factor for early mortality among patients with cancer","volume":"34","author":"Ramsey","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.06.008_bib0023","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience","volume":"18","author":"Zafar","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2024.06.008_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01067","article-title":"Association of major adverse financial events and later-stage cancer diagnosis in the United States","author":"Warren","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502400243X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502400243X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T11:09:54Z","timestamp":1729595394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502400243X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S215226502400243X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival Among Patients With Multiple Myeloma in the United States Military Health System Compared to the Surveillance, Epidemiology, and End Results (SEER) Program","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}